Sergio Ramos
About Sergio Ramos
Sergio Ramos serves as the Global Controller at Instil Bio, where he has worked since 2020. He has over 12 years of experience in the biotechnology industry and holds a Bachelor's degree in Business Administration with an accounting concentration from California State University, Fullerton.
Work at Instil Bio
Sergio Ramos has been serving as the Global Controller at Instil Bio since 2020. In this role, he is responsible for ensuring adherence to Sarbanes-Oxley (SOX) and Generally Accepted Accounting Principles (GAAP) standards. He has successfully implemented accounting systems and improved accounting processes within the organization. His work supports the financial integrity of the company as it develops cell therapies for cancer patients.
Education and Expertise
Sergio Ramos earned a Bachelor's degree in Business Administration with a concentration in Accounting from California State University, Fullerton, completing his studies from 2004 to 2008. He possesses skills in SEC reporting, procure-to-pay processes, financial planning and analysis, management, external audit, and manufacturing process improvement. His educational background and expertise contribute to his effectiveness in financial management within the biotechnology sector.
Background
Sergio Ramos has over 12 years of experience in the biotechnology industry. His career includes various roles in financial management and accounting. He has held positions at Kite Pharma, where he progressed through several roles, including Sr. Accounting Manager, Associate Director of Accounting, and Director of Finance. Prior to his tenure at Kite Pharma, he worked as a Senior Auditor at KPMG and Squar Milner, and as an Accounting and Financial Reporting Manager at ISC8.
Achievements
During his career, Sergio Ramos has successfully implemented accounting systems and improved accounting processes at Instil Bio. His previous roles at Kite Pharma involved significant contributions to financial planning and analysis, which enhanced the financial operations of the organization. His commitment to delivering accurate and timely financial information has been instrumental in supporting the development of innovative therapies in the biotechnology field.